How Will the Market React to Aclaris Therapeutics Inc (ACRS) Stock Getting a Neutral Rating

Overall market sentiment has been neutral on Aclaris Therapeutics Inc (ACRS) stock lately. ACRS receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.

Aclaris Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ACRS!

See Full ACRS Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ACRS Stock Today?

Aclaris Therapeutics Inc (ACRS) stock is trading at $1.20 as of 2:43 PM on Tuesday, Mar 26, a rise of $0.04, or 3.02% from the previous closing price of $1.16. The stock has traded between $1.16 and $1.21 so far today. Volume today is less active than usual. So far 358,070 shares have traded compared to average volume of 1,274,552 shares.

More About Aclaris Therapeutics Inc

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. Click Here to get the full Stock Report for Aclaris Therapeutics Inc stock.